Testing bevacizumab with chemo and immunotherapy for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies whether adding bevacizumab to chemo plus immunotherapy (including atezolizumab) can improve outcomes in extensive-stage small cell lung cancer (ES-SCLC) that has spread to the liver. It may help by blocking tumor blood vessel growth while boosting anti-cancer immune and treatment effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed extensive-stage small cell lung cancer (ES-SCLC) and liver metastases seen on scans
- You have not had any prior treatment for ES-SCLC (chemo/immunotherapy-naïve)
- Your cancer has at least one measurable spot on scans that can be followed over time
- If you have brain metastases, they must be limited to certain areas and must be stable after any treatment
- Your overall health and blood counts must be strong enough for treatment (based on recent lab tests)
- Your blood pressure, urine protein level, bleeding/clot history, and medications must meet safety rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new approach for extensive-stage small cell lung cancer (SCLC) that has not been treated before. It combines a high-dose chemotherapy regimen with a drug called adebrelimab (an immunotherapy) and a stem cell transplant to help your body recover. The goal is to see if this powerful combination can work better than standard treatment.
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation therapy to see if it works better than standard treatment for people with extensive-stage small cell lung cancer who have not been treated before.
This trial tests a new combination of drugs (QL1706, anti-angiogenesis therapy, and chemotherapy) for people with extensive-stage small cell lung cancer who have not received any prior treatment. The goal is to see if this combination works better than standard care.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.